Biomarin Pharmaceutical (BMRN) EBIAT (2017 - 2025)
Historic EBIAT for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Q3 2025 value amounting to -$30.7 million.
- Biomarin Pharmaceutical's EBIAT fell 12898.19% to -$30.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $520.4 million, marking a year-over-year increase of 6147.43%. This contributed to the annual value of $426.9 million for FY2024, which is 15462.08% up from last year.
- According to the latest figures from Q3 2025, Biomarin Pharmaceutical's EBIAT is -$30.7 million, which was down 12898.19% from $240.5 million recorded in Q2 2025.
- In the past 5 years, Biomarin Pharmaceutical's EBIAT registered a high of $240.5 million during Q2 2025, and its lowest value of -$57.9 million during Q4 2021.
- In the last 5 years, Biomarin Pharmaceutical's EBIAT had a median value of $40.4 million in 2023 and averaged $56.2 million.
- As far as peak fluctuations go, Biomarin Pharmaceutical's EBIAT crashed by 44001.64% in 2021, and later surged by 828273.09% in 2023.
- Over the past 5 years, Biomarin Pharmaceutical's EBIAT (Quarter) stood at -$57.9 million in 2021, then surged by 99.57% to -$249000.0 in 2022, then skyrocketed by 8282.73% to $20.4 million in 2023, then surged by 513.22% to $124.9 million in 2024, then plummeted by 124.61% to -$30.7 million in 2025.
- Its EBIAT was -$30.7 million in Q3 2025, compared to $240.5 million in Q2 2025 and $185.7 million in Q1 2025.